Sophie Piperno-Neumann

List of Publications by Year in Descending Order

93 papers	3,523 citations	31 h-index	58 g-index
103 ext. papers	4,628 ext. citations	7.4 avg, IF	4.71 L-index

#	Paper	IF	Citations
93	Metastatic uveal melanoma: The final frontier.. *Progress in Retinal and Eye Research*, **2022**, 101041	20.5	3
92	Helping Patients Communicate With Oncologists When Cancer Treatment Resistance Occurs to Develop, Test, and Implement a Patient Communication Aid: Sequential Collaborative Mixed Methods Study.. *JMIR Research Protocols*, **2022**, 11, e26414	2	
91	Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma.. *Pediatric Blood and Cancer*, **2022**, e29725	3	1
90	Splicing Patterns in -Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. *Cancer Discovery*, **2021**, 11, 1938-1951	24.4	9
89	Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. *Cancers*, **2021**, 13,	6.6	2
88	REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).. *Journal of Clinical Oncology*, **2021**, 39, TPS11576-TPS11576	2.2	
87	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. *Journal of Clinical Oncology*, **2021**, 39, 11507-11507	2.2	4
86	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. *Journal of Clinical Oncology*, **2021**, 39, 9509-9509	2.2	2
85	Determinants of the access to remote specialised services provided by national sarcoma reference centres. *BMC Cancer*, **2021**, 21, 631	4.8	3
84	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. *European Journal of Cancer*, **2021**, 150, 108-118	7.5	3
83	Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. *Cancers*, **2021**, 13,	6.6	5
82	ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 3-11	5.1	7
81	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. *Bulletin Du Cancer*, **2021**, 108, 163-176	2.4	3
80	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. *New England Journal of Medicine*, **2021**, 385, 1196-1206	59.2	63
79	Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome. *Scientific Reports*, **2021**, 11, 23429	4.9	
78	Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. *Molecular Cancer Therapeutics*, **2020**, 19, 1031-1039	6.1	14
77	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 446-455	21.7	92

76	Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. *Annals of Surgical Oncology*, **2020**, 27, 1818-1827	3.1	8
75	A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.. *Journal of Clinical Oncology*, **2020**, 38, 11506-11506	2.2	
74	Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years. *Journal of Adolescent and Young Adult Oncology*, **2020**, 9, 172-182	2.2	9
73	Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival. *JAMA Ophthalmology*, **2020**, 138, 182-188	3.9	11
72	Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. *European Journal of Cancer*, **2020**, 124, 152-160	7.5	16
71	Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. *Annals of Surgical Oncology*, **2020**, 27, 1693-1699	3.1	3
70	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. *American Journal of Roentgenology*, **2020**, 215, 1539-1548	5.4	9
69	Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. *International Journal of Cancer*, **2020**, 146, 413-423	7.5	10
68	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. *Cancers*, **2019** , 11,	6.6	4
67	Evolutionary Routes in Metastatic Uveal Melanomas Depend on Alterations. *Clinical Cancer Research*, **2019**, 25, 5513-5524	12.9	31
66	Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. *BMJ Open*, **2019**, 9, e025877	3	14
65	PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma. *Cancers*, **2019**, 11,	6.6	19
64	Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years. *International Journal of Cancer*, **2019**, 145, 2135-2143	7.5	6
63	Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. *Lancet Oncology, The*, **2019**, 20, 1263-1272	21.7	69
62	So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020. *Cancers*, **2019**, 11,	6.6	28
61	Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI. *Cancers*, **2019**, 11,	6.6	13
60	Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas. *Modern Pathology*, **2019**, 32, 1786-1794	9.8	12
59	Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC).. *Journal of Clinical Oncology*, **2019**, 37, TPS11078-TPS11078	2.2	1

58	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. *Lancet Oncology, The*, **2019**, 20, 120-133	21.7	134
57	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 639-648	21.7	47
56	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. *JAMA Oncology*, **2018**, 4, 93-97	13.4	191
55	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. *European Journal of Cancer*, **2018**, 99, 28-36	7.5	9
54	Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases. *Journal of Pathology: Clinical Research*, **2018**, 4, 227-240	5.3	36
53	Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.. *Journal of Clinical Oncology*, **2018**, 36, 11507-11507	2.2	2
52	Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.. *Journal of Clinical Oncology*, **2018**, 36, 11508-11508	2.2	4
51	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. *Journal of Clinical Oncology*, **2018**, 36, 11574-11574	2.2	6
50	Selumetinib-based therapy in uveal melanoma patient-derived xenografts. *Oncotarget*, **2018**, 9, 21674-21686	5.9	15
49	Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.. *Journal of Clinical Oncology*, **2018**, 36, 11523-11523	2.2	
48	Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. *European Journal of Cancer*, **2018**, 88, 57-66	7.5	38
47	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). *Journal of Clinical Oncology*, **2018**, 36, 1232-1239	2.2	135
46	Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). *Oncologist*, **2018**, 23, 948-955	5.7	9
45	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. *Journal of Clinical Pharmacology* , **2018**, 58, 1541-1549	2.9	17
44	Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. *Nature Communications*, **2018**, 9, 1866	17.4	65
43	Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts. *Pigment Cell and Melanoma Research*, **2017**, 30, 317-327	4.5	18
42	Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. *European Journal of Cancer*, **2017**, 75, 98-108	7.5	45
41	The biological and prognostic significance of angiotropism in uveal melanoma. *Laboratory Investigation*, **2017**,	5.9	12

40	CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. *OncoImmunology*, **2017**, 6, e1331193	7.2	80
39	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. *European Journal of Cancer*, **2017**, 83, 125-131	7.5	79
38	Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study. *BMC Cancer*, **2017**, 17, 419	4.8	2
37	Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.. *Journal of Clinical Oncology*, **2017**, 35, 11053-11053	2.2	7
36	A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ).. *Journal of Clinical Oncology*, **2017**, 35, 9502-9502	2.2	9
35	Undifferentiated endometrial sarcomas (UES): Results of a French sarcoma group (FSG) retrospective series of 52 patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, e17109-e17109	2.2	1
34	First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. *Anticancer Research*, **2017**, 37, 1403-1407	2.3	4
33	Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial.. *Journal of Clinical Oncology*, **2017**, 35, 11052-11052	2.2	2
32	Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 11047-11047	2.2	
31	Expression and prognostic significance of PDGF ligands (A, B, C, and D) and PDGFR (A, B, and L) in soft-tissue sarcomas and GIST.. *Journal of Clinical Oncology*, **2017**, 35, 11067-11067	2.2	
30	Weekly paclitaxel (WP) +/- bevacizumab (B) in angiosarcoma (AS) patients (pts): Analysis of prognostic/predictive factors from a randomized phase 2 trial.. *Journal of Clinical Oncology*, **2017**, 35, 11024-11024	2.2	
29	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 1732-1742	21.7	141
28	Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group. *American Journal of Ophthalmology*, **2016**, 168, 217-226	4.9	29
27	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 1070-1080	21.7	120
26	Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. *Nature Communications*, **2016**, 7, 10615	17.4	223
25	Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. *Oncologist*, **2016**, 21, 281-2	5.7	27
24	Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. *Oncotarget*, **2016**, 7, 33542-56	3.3	38
23	Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14) **2016**, 57, 1982-90		14

22	Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 457-64	21.7	70
21	Diffusion-weighted MRI for uveal melanoma liver metastasis detection. *European Radiology*, **2015**, 25, 2263-73	8	8
20	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. *Journal of Clinical Oncology*, **2015**, 33, 2797-802	2.2	117
19	Upcoming translational challenges for uveal melanoma. *British Journal of Cancer*, **2015**, 113, 1249-53	8.7	16
18	Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTCSS (Observatoire de lSUtilisation des ThEapies CiblEs dans les Sarcomes). *BMC Cancer*, **2015**, 15, 854	4.8	21
17	Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. *European Journal of Cancer*, **2015**, 51, 742-50	7.5	70
16	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 312-9	21.7	67
15	Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. *European Journal of Cancer*, **2015**, 51, 202-9	7.5	20
14	Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. *Molecular Oncology*, **2014**, 8, 1508-20	7.9	71
13	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. *European Journal of Cancer*, **2014**, 50, 1137-47	7.5	85
12	Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. *British Journal of Ophthalmology*, **2014**, 98, 769-74	5.5	80
11	The off-label use of targeted therapies in sarcomas: the OUTCSS program. *BMC Cancer*, **2014**, 14, 870	4.8	19
10	Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. *International Journal of Cancer*, **2014**, 134, 1207-13	7.5	129
9	Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9030-9030	2.2	27
8	Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. *PLoS ONE*, **2014**, 9, e80836	3.7	34
7	Patient-derived xenografts recapitulate molecular features of human uveal melanomas. *Molecular Oncology*, **2013**, 7, 625-36	7.9	37
6	SF3B1 mutations are associated with alternative splicing in uveal melanoma. *Cancer Discovery*, **2013**, 3, 1122-1129	24.4	282
5	Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. *Clinical Cancer Research*, **2012**, 18, 3934-41	12.9	63

4	Therapeutic options in metastatic uveal melanoma. *Developments in Ophthalmology*, **2012**, 49, 166-181		28
3	Bone sarcomas: from biology to targeted therapies. *Sarcoma*, **2012**, 2012, 301975	3.1	19
2	Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. *Clinical Cancer Research*, **2010**, 16, 2352-62	12.9	120
1	Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases **2009**, 50, 2572-80		107